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1. Introduction
Mesenchymal stem cells (MCSs) are refined as undifferencitaed cells that are capable of self
renewal and differentiation into several cell types such chondrocyte, adipocyte osteocyte,
myocyte and neuron-like cells. MSC can be isolated from bone marrow umbilical cord blood
adipose tissue placenta. Although bone marrow(BM) has been regarded as a major source of
MSC umbilical cord blood has been regarded as an alternative source for isolation of MSC.
Human umbilical cord blood derived mesenchymal stem cell (hUCB-MSCs) have a capacity
similar to that of BM-MCSs for multi-lineage differentiation
Researchers are interested in these cells because of their ability of differentiating into multiple
mesenchymal and non mesenchymal lineages. Furthermore, MSCs evoke only minimal
immunoreactivity and they display trophic, anti-inflammatory, and immunomodulatory
capacities, through secretion of bioactive soluble factors with anti-inflammatory and immu‐
nomodulatory effects in vivo. These properties were confirmed by both experimental and
clinical studies which demonstrated that the MSCs support hematopoiesis and enhance the
engraftment of hematopoietic stem cells (HSC) after cotransplantation, which may contribute
to a reduced incidence of graft versus host disease (GVHD). [1,2,3,4,5,6,7]
The galectins are a family of soluble lectins characterized by their affinity for b-galactoside
residues. These proteins have recently attracted increasing attention because of theirinvolve‐
ment in various physiological and pathological processes. In addition, these proteins have
recently attracted increasing attention of cancer biologists because of their essential functions
including development, differentiation, cell–cell adhesion, cell–matrix interaction, growth
© 2013 Jenhani; licensee InTech. This is an open access article distributed under the terms of the Creative
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regulation, apoptosis, RNA splicing, and tumor metastasis. Also, it has been shown that
galectins’ levels are altered in various cancers. [8,9,10]
Galectins-1,3,9 and 13 were among the best characterized members of this family. These
galactins possesses several functions and were expressed in many tissues.
Given the importance of galectins, we investigated in this work, their expression by BM MSCs
in different culture mediums
2. Materiel and methods
2.1. Preparation of hBM-MSC
MSCs were extracted and isolated from two sources adult the bone marrow. H- BM cells was
harvested from the sternum or the iliac crest of healthy donors [20] after obtaining an informed
consent was obtained in the Bone Marrow Graft National Center of Tunisia. The mean age of
donors was 30 ± 2 years (range, 15-40 years).
MSCs were isolated using the classical plastic adhesion method. Mononuclear cells (MNCs)
were isolated from hBM by density gradient (Ficoll Hypaque solution d=1. 077) centrifugation.
After centrifugation at 800 g for 20 min at room temperature. MNC layer was removed from
the interphase and washed twice with Hank’s buffered salt solution and seeded into uncoated
T25 or T75 flasks (Becton Dickinson, Bedford, MA, USA) at a cell concentration of 1×105 cells/
cm2 for BM cells and cultured in three condition mediums:
i. (M1) : basic growth medium consisting of alpha-Minimum Essential Mediums (alpha
-MEM, Gibco BRL, Grand Island, NY, USA), supplemented with 10 % (v/v) fetal
bovine serum (Sigma-Aldrich, Bornem, Belgium),100U/mL penicillin, 0. 1 mg/mL
streptomycin (Gibco BRL), 2Mm L-glutamine (Gibco BRL), 0. 025 mg/mL fungizone
(Gibco BRL) 10% (v/v) of prescreened fetal bovine serum (FBS; Perbio Hyclone,
Logan, Utah, USA) and 1 ng/mL fibroblast growth factor2 (FGF2) (AbCys, Paris,
France)
ii. (M2): basic growth medium with fetal bovine serum and FGF2 replaced by 5 % (v/v)
human patelet lysed (HPL)
iii. (M3): basic growth medium with fetal bovine serum and FGF2 replaced by 10 %
(v/v) h (HPL). Cell cultures were incubated at 37°C in a 5% CO2 humidified atmos‐
phere. The medium was changed twice weekly thereafter. When reaching 60% -80%
confluence, the adherent cells were detached after treatment with 0. 05% (v/v) trypsin/
1 mM EDTA solution (Gibco BRL) and expanded by replating at a lower density at
103 cells per cm2. All the studies were performed after 2 passages (P2).
2.2. Induction of the differentiation directions
We induced the differentiation of the MSCs when they reached the confluence. We used three
differentiation mediums according to the focused differentiation line:
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2.2.1. Osteogenic induction (O)for analysis galectins expression
At 50% confluence, the cells were cultured for 14 days in DMEM-HG (High Glucose 4. 5 g/L)
containing 2% FBS, 0. 1 µM dexamethasone (Sigma), 2 mM β-glycerolphosphate (Sigma), and
100 µM ascorbate-2-phosphate (Sigma) with medium changes every 3 days. After 2 weeks of
induction, the cells were stained according to Von Kossa’s and Alizarin Red methods to detect
the presence of calcium deposition into osteocytes.
2.2.2. Adipogenic induction (A) for analysis galectins expression
The adipogenic induction medium consisted of DMEM-LG (Low Glucose 1g/L) supplemented
with 20% FBS, 1 µM/L dexamethasone, 0. 5 mmol/L isobutylmethylxanthine (IBMX; Invitro‐
gen), and 60 µmol/L indomethacin (Sigma). Adipogenic differentiation was evaluated after 2
weeks of induction, by the cellular accumulation of neutral lipid vacuoles that were stained
with Nile Red (Sigma) and observed by fluorescent microscopy.
2.2.3. Vascular smooth muscle induction (V) for analysis galectins expression
Vascular smooth muscle (VSM) differentiation was obtained in a Mc Coy’5A medium
supplemented with 12. 5% FBS, 12. 5% HS (Horse Serum, Invitrogen), 20 µM L-glutamine, 0,8
mM L-serine, 0,15 mM L-asparagine, 1 Mm sodium pyruvate, 5 mM sodium bicarbonate, 1
µM hydrocortisone and amphotericin B and antibodies. The medium was changed every 4
days. The VSM differentiation was evaluated after 3 weeks of induction.
2.3. Immunophenotyping of mesenchymal stem cells by flow cytometry
MSCs were immunophenotypically characterized by flow cytometry using the following
fluorochrome (FITC PE, PerCP) marked monoclonal antibodies anti : CD45, CD105, CD106,
CD90,CD49, CD34, et CD73 and CD14 (Becton Dickinson and Company BD Biosciences San
Jose CA).
2.4. Detection of galectins (Gal-1, Gal-9 Gal-11 and Gal-13), by flow cytometry
To reveal the expression of the galactin we used biotynaled antibodies against human
recombinant galectin (Gal-1, Gal-9, Gal-11 and Gal-13). Thus we incubated 1,5 106 MSCs cells
with the antibody which is specific to the focused galectin, for 30 minutes, at 4° C. We incubated
also the MSCs with a control antibody which doesn’t recognize any protein, but has the same
isotype to evaluate a background noise which correspond to non-specific fixation of the
primary antibody.
The MSCs were washed 2 times with PBS 1X solution, then incubated for 30 minutes with
Streptavidin coupled with a phycoerythrin (PE) fluorochrome phycoerythrin (PE). Flow
cytometry analysis was performed on a FACS calibur, and data were analyzed using CellQuest
software (Becton–Dickinson, BD Biosciences San Jose, CA).
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2.5. Galectins immunofluorescence detection
MSCs were fixed using 4% Methanol for 30 minutes at +4°C and washed with PBS. The primary
antibodies against many anti-antibodies: Gal-1-Streptavidine, Gal-3-Streptavidine, Gal-9-
Streptavidin and Gal-13 Streptavidin were diluted in 10% BSA and 0. 2% Tween 20 (1:100) and
were incubated at 4°C for 12h followed by washings 3 times with PBS. For immunofluorescence
non-specific binding sites were blocked with 10% BSA-PBS. For secondary immunofluorecence
Biotine –fluoroscein were diluted in 10% BSA-PBS and incubated for 60 min at +4°C in the
dark. Images were taken with camera and with inverse fluorescence microscopy
2.6. RNA isolation and reverse transcription – Polymerase chain reaction before and after
induction
2.6.1. RNA isolation
For RT-PCR, Total RNA was extracted from cell culture in total confluence [90% ) using
TRIZOL reagent (Gibco BRL) according to the manufacturer’s instructions. Reverse transcrip‐
tion was carried out using PrimeScript™RTase (Takara: Japan and Applied Biosystems) and
the cDNA fragments were amplified using RNase Inhibitor (Takara: Japan and Applied
Biosystems): For each reaction, we mixed 5 µl of ARN or 5µl of distilled water (for the control),
6 µl desoxyribonucleotides (dNTP)(TaKaRa Japan and Applied Biosystems), 1µl primers
specific of the gene sequence (table 1) et 0. 5 µl of enzyme la Taq polymerase enzyme (Takara:
Japan and Applied Biosystems).
2.6.2. RT-PCR before and after induction for the confirmation of the three directions of differentiation
After denaturation at 65°C for 5 min, amplification was carried out by 30 cycles at 30°C for 10
min, 42°C for 60 min and 95°C for 5 min. Primers used are shown in Table 1. The expression
of the following genes were analyzed before (D0) and after differentiation (D14) into three
directions of differentiation: osteogenesis (O), adipogenesis (A) and vascular smooth muscle
(V). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene expression was used as
control. The sequences of the oligonucleotides were reported in Table 1. Thermocycling was
performed with a gradient thermocycler (Takara, Japan and Applied Biosystems). The analyse
of the PCR products was carried out in an electrophoresis gel 1% (Sigma).
Construct Sequence forward Sequence reverse
GAPDH 5’- AATCCCATCACCATCTTCCAGG-3’ 5’-AGAGGCAGGGATGATGTTCTGG-3’
PAL 5’-CTGGACCTCGTTGACACCTG-3’ 5’-GACATTCTCTCGTTCACCGC-3’
Runx2 5’-AACTTCCTGTGCTCGGTGCTG-3’ 5’-GGGGAGGATTTGTGAAGACGG-3’
LPL 5’-AAAGCCCTGCTCGTGCTGAC-3’ 5’-TAAACCGGGCCACATCCTGT-3’
PPRγ 5’-GGAGAAGCTGTTGGCGGAGA-3’ 5’-TCAAGGAGGCCAGCATTGTG-3’
ASMA 5’-TCATGATGCTGTTGTAGGTGGT-3’ 5’-CTGTTCCAGCCATCCTTCAT-3’
Table 1. Sequences of the primers used in RT-PCR study
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2.6.3. Reverse transcription – Polymerase chain reaction before and after induction for
Galectin1,Gal-9,Gal-11 and Gal-13 expression
After denaturation at 65°C for 5 min, amplification was carried out by 30 cycles at 30°C for 10
min, 42°C for 60 min and 95°C for 5 min. Primers used are shown in Table 2.
Construct Sequence forward Sequence reverse
GAPDH 5’AATCCCATCACCATCTTCCAGG3’ 5’AGAGGCAGGGATGATGTTCTGG3’
Gal 1 5’ATGGCTTGTGGTCTGGTC3’ 5’TCAGTCAAAGGCCACACA3’
Gal 9 5’ATGGCCTTCAGCGGTTCC3’ 5’CTATGTCTGCACATGGGTCAG3’
Gal 11 5’ATGAGTCAGCCCAGTGGG3’ 5’TCAGGAGTGGACACAGTAGAG3’
Gal 13 5’ATGTCCCTGACCCACAG3’ 5’TCAATCGCTGATAAGCACT3’
Table 2. Sequences of the primers used in RT-PCR study
Thermocycling was performed with a gradient thermocycler (Takara, Japan and Applied
Biosystems). The analyse of the PCR products was carried out in an electrophoresis gel 1%
(Sigma).
2.7. Statistical analysis
Data are expressed as mean ± standard error of the mean. Statistical comparisons were
performed using the t-test student or Mann Whitney test with the program Graphpad, version.
5. A one-way analysis of variance (ANOVA) was done for paired samples; p < 0. 05 was
considered to be statistically significant.
3. Results
3.1. Morphologic analysis of MSCs derived from bone marrow in terms of culture mediums
To prepare MSCs cultures, we isolated mononuclear cells (MNCs) from bone marrow (hBM).
The MNCs derived from bone marrow were put in a density of 1. 10⁶ cells / cm².
Adherent cell populations from the MNC fraction of hBM samples were generated by
expansion culture using 3 different media: (M1) Alpha MEM with 10% FBS and 1 ng/mL
FGF2, (M2) Alpha MEM with 5% HPL, (M3) Alpha with 10% HPL. After two weeks of culture,
an adherent and stable cell layer was obtained from BM derived MNC with all medium Mean
time for the primary culture to reach subconfluence was 15 days. After one passage(P1),
adherent cells displayed a fibroblast-like morphology in culture plate (n=20). The figure 1
showed a particular morphology of cultured MSC.
Human Platelet Lysate for MSC Expression Galectins
http://dx.doi.org/10.5772/55383
37
   hM
M1 
    
 
M2 
 
M3 
 
SC-BM 
Figure 1. Morphological characterization of hMSC-BM cultured in different media in the P2 (passage): M1: (10% FBS
+FGF2), M2:(5% HPL), M3:(10% HPL).
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Figure 2. Representative flow cytometry analysis of BM-MSCs.Comparison of membrane antigen expression of BM-
MSCs cultured at P2 in different media: M1 :(10% FBS+FGF2) M2: (5% HPL), M3: (10% HPL)
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Also MSCs were immunophenotypically characterized by flow cytometry. This analysis
revealed that MSCs were uniformly positive for CD73 CD90 CD105 CD106 but negative for
CD14 CD34 and CD45 (figure 2).
The influence of HPL or FBS on the osteogenic and adipogenic differentiation potential of
MSCs was investigated after appropriate induction at the second passage (P2). Cells grown in
HPL or FBS deposited an extensive mineralized matrix when cultured for 2 weeks in an
osteogenic medium [2% FBS), as demonstrated by strong alizarin red staining. These cells also
efficiently differentiated into the adipogenic lineage, as indicated by Oil Red O staining of lipid
droplets in the cytoplasm following culture in an adipogenic medium.
All populations of BM-MSCs cultured in different conditions with the HPL showed osteogenic,
Vascular smooth muscle and chondrogenic differentiation capacity. The difference appears in
adipogenic differentiation with 10% HPL (Fig 3 ).
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Figure 3. Morphological characterization of hBM- MSCs derived cultured in different media M1, M2 and M3 at P2 and
Osteogenic, chondrogenic, adipogenic, and vascular smooth muscular differentiation capacity assessed by staining
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To confirm their differentiation potential, after P1 MSCs were plated in specific induction
mediums to generate for adipocytes, osteoblasts, or chondrocytes.
To select the differentiated MSCs, we used the RT-PCR to search markers specific for the three
differentiation directions. These markers are the alkalin phosphatase (PAL) as osteoblast specific
marker the lipoprotein lipase (LPL)as specific of the adipocyte line and the actin-ASMA specific
of vascular smooth muscles line. The positive control is the GAPDH. These markers were not
expressed before the induction of the differentiation and presented an overexpression after the
14th day from the induction of specific differentiation in the three expansion mediums (M1, M2,
et M3) demonstrating the multipotent nature of the MSCs (figure 4).
 
                     A                                                                 B  
          BM (D0)                                                      BM (D14)  
M1          M2           M3                               M1          M2          M3           
ASMA        
PPRγ          
 Runx 2      
  PAL          
GAPDH      
 
Figure 4. RT-PCR analyses of vascular smooth muscle (ASMA), adipogenic (PPRγ), and osteogenic (Runx2, PAL) mark‐
ers prior to (D0) (A) and after 14 days of differentiation induction (D14) (B) of BM-derived MSCs previously cultured in
expansion media (M1, M2, M3)
3.2. Detection of galectins in MSCs in terms of the culture mediums by flow cytometry
MSCs from different BM samples were characterized by flow cytometry with a panel of
biotynaled antibodies against human recombinant galectin (Gal-1, Gal-9, Gal-11 and Gal-13)
at P2 after culture in the three mediums (M1, M2, et M3). Flow cytometry analysis revealed
that MSC derived-hBM constitutively expressed galectins (Gal-1, Gal-9, Gal-11, Gal-13) at
Human Platelet Lysate for MSC Expression Galectins
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different mediums but with unequal percentages. We noticed that galectins 9 and 11 are more
expressed by cells derived from hBM with an average of [88. 1 ± 1. 8 % ) in M1 Meduim in
comparison to M2 (16,8 ± 3. 9 % ) and M3 (11,6 ± 3. 9% ) with p < 0. 01.
We noticed also that galectin 1 is expressed with in average of (91. 2 ± 1. 4 % ) at P2 after culture
in the three mediums (M1,M2,M3). In the contrary no expression of galactin 13 have been noted
in any medium. (figure 5)
Figure 5. Galectins Gal-1, Gal-9,Gal-11 and Gal-13 antigen expression of BM-MSCs cultured at P2 in different media:
M1 (10% FBS+FGF2) M2(5% HPL), M3 (10% HPL) by flow cytometry
3.2.1. Expression of galectins of MSC-BM by microscopy immunofluorecence
Immunofluorecsence of galectin-1 in MSC of normal adult bone marrow was showed expres‐
sion in three mediums M1,M2,M3. Following this technique, we are also identified galectins
gal-9 and gal-11 expression but only in standard medium M1. No expression of gal- 13 have
been reveled by hBM-CSM cultured in all media M1,M2 and M3. we are determined the
localization of galectin mostly in nucleus cells. (Fig6).
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Figure 6. Immunofluorescence Galectin-1, Galectin-9, Galectin -11 and Galactin-13 expression by cultured at P2 in dif‐
ferent media: M1 (10% FBS+FGF2) M2 (5% HPL), M3 (10% HPL)
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Figure 7. RT –PCR Galectin-1, Galectin-9, Galectin -11 and Galactin-13 expression by cultured at P2 in different media:
M1 (10% FBS+FGF2) M2 (5% HPL), M3 (10% HPL) and after differentiation process ( O: osteogenic induction, A: Adipo‐
genic induction,V: Vascular Smooth Muscle induction, GAPDH : Glyceraldheyde 3-phospate dehydrogenase, PM:
Weight molecular )
3.3. RT –PCR galectin-1,Gal-9,Gal-11 and Gal-13 expression by hBM-MSCs
By RT-PCR, we evaluated the messenger RNA expression of Galectin-1,Galectin-9, Galectin-11
and Galectin -13 in hBM-MSCs before and after differentiation to the three direction : osteo‐
blastic [0), adipocyte (A) and to vascular smooth muscle (VSM).
We had a positive results for hBM-MSCs both before their differentiation and after the
induction of the three differentiation directions:
• before the induction of the differentiation process :Gal-1 was expressed by hBM- MSCs in
the standard medium M1 (MEM+ FGF2) and also in the three mediums (M2, M3, et M4)
which contain the human platelet lysat (HPL). While, after the induction of the MSCs
differentiation, Gal-1 was only expressed in MSCs cultivated in mediums containing the
HPL (M2, M3), in the three differentiation directions (O, A, VML)
• Concerning the expression of Gal-9 by BM-MSCs: we observed that Gal-9 was expressed by
undifferentiated BM-MSCs cultivated in the standard medium (M1: MEM+ FGF2), but
absent in MSCs cultivated in mediums containing the HPL (M2, M3). However, after
inducing the differentiation process, this galectin was absent in MSCs of the standard
medium and had a very low expression in mediums containing the HPL (M2, M3).
• Regarding the expression of Gal-11 by BM-MSCs, we found that Gal- 11 was expressed by
undifferenciated BM-MSCs, in the standard medium M1 (MEM+ FGF2) but absent in BM-
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MSCs cultivated in M2, M3, and M4. And After the MSCs differentiation Gal-11 was no
more expressed in the standard culture’s medium (M1 : MEM+ FGF2), while MSCs culti‐
vated in mediums containing the HPL (M2, M3) expressed the Gal- 11 in adipocytes (A) and
vascular smooth muscle cells (VML). As to Gal-13, we reported that this galectin wasn’t
expressed by the undiferenciated MSCs neither in the standard medium nor in the mediums
containing the HPL (M1, M2, and M3). Whereas, after the MSCs differentiation, Gal-13 was
only expressed by adipocytes. (figure 5)
4. Discussion
Multipotent mesenchymal stromal cells (MSCs) have generated a great debate as a potential
source of cells for cell-based therapeutic strategies primarily owing to their intrinsic ability to
self renew and differentiate into functional cell types that constitute the tissue in which they exist
and also because MSCs express a large number of molecules including the galectins. [11,12]
The galectins are a family of soluble lectins characterized by their affinity for β-galactoside
residues. In recent years, galectins have become a major focus of investigation because of their
involvement in various physiological and pathological processes. [13,14]
Given that galectins have been shown to have important effects [13,14] we decided to evaluate
the expression of galectins (Gal-1, Gal-3, Gal-9 and Gal-13) by MSCs.
In this study we analyzed MSCs cultured and expanded in three conditions mediums: basic
growth medium consisting of alpha-Minimum Essential Medium in which HPL replaced FBS
in order to investigate their morphology, plasticity, proliferation differentiation to osteoblasts,
adipocytes, and vascular smooth muscles and their capacity to express galectins in terms of
the mediums’ compositions. [15,16]
In our laboratory MSCs were characterized and defined according to the International Society
for Cellular Therapy minimal criteria. [17,18]. So first, we demonstrated that BM-MSC adhered
to plastic. Second as measured by flow cytometry all of MSC derived from BM-MSC were
nearly 100% positive for the makers CD90 CD105, and CD73 (≥95% ), while they lack the
expression of CD45 CD34, and CD14 (≤ 2% ). Third, BM-MSC differentiated to osteoblasts
adipocytes and vascular smooth cells.
First, we investigated the effect of culture mediums on the adherence and the proliferation of
MSCs. Then we demonstrated that the three mediums allow the adherence of MSCs to plastic
and their proliferation, but the percentage of confluence and the times it takes to get it, change
in terms of the composition of the culture medium. So, the culture mediums containing 5% HPL
induced the best MSCs confluence. Thus the most important confluence of the bone marrow’s
MSCs was reached at the first passage (P1) in the culture’s medium 5% HPL after 30 days from
their implantation. So, we confirmed that HPL-expanded MSCs show a significantly higher
proliferation rate, in comparison with MSCs expanded in the standard medium. So, we can use
the HPL as a substitute of FBS in mediums specific to the culture of MSCs destined for clinical
applications, to avoid a possible xenogenic contamination caused by the FBS. [19]
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The expansion-promoting effect of the HPL is likely to result from the high concentration of
natural growth factors that HPL contains. In fact platelet granules contain many growth factors,
including platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), insulin-like
growth factor (IGF), transforming growth factor (TGFb), platelet factor 4 (PF-4), and platelet-
derived epidermal growth factor (PDEGF) [20,21]. These growth factors, which are released from
platelet lysate, have been shown to enhance MSC expansion in vitro. [20, 21,22,23,24]
Second, we analyzed the morphology of MSC, and observed fibroblast-like cells in BM. Thus
the MSCs formed a monolayer of homogenous spindle-shaped cells with a whirlpool-like
array. This result is in accordance with the literature. [25]. However, two cell phenotypes were
observed among fibroblast-like BM-MSC colonies: thin spindle shaped MSC and star-shaped
MSC. These BM-MSC two phenotypes were described by Wolgang et Wagnera and al [25]
To detect the expression of galectins Gal-1, Gal-9, Gal-11 and Gal-13 by MSCs, we used two
techniques which are the flow cytometry (FC) and the RT-PCR. We searched the expression
of galectins in MSCs cultivated in the three culture mediums: the standard medium: alpha-
MEM+ FGF2, the medium (with 5% HPL), the medium (with 10% HPL).
The flow cytometry revealed that all the galectins of interest (Gal-1, Gal-3, Gal-9, and Gal-13)
are expressed in BM-MSCs, in above mentioned culture mediums,. It thus becomes clear that
expression percents of galacetins revealed by the flow cytometry in hBM-MCSs depend on
two parameters which are the composition of the medium and the type of the galectin.
Thus, we observed mainly that the best Galectins’ expression was visualized in the standard
medium (alpha-MEM /FGF2).  Previous studies  have shown that  the supplementation of
fibroblast growth factor 2 (FGF2) in vitro selects for the survival of a large number of of MSCs
enriched in pluripotent mesenchymal precursors enhances the growth of MSCs maintains their
multilineage differentiation potential during in vitro expansion and prolongs their life span [26].
So, this data and our observation suggest that the increase of galectins in the presence of FGF2
is due to the improvement of the growth the proliferation and differentiation potential of MSCs.
Then, when comparing the means of the galectins’ expression by the MSCs we concluded that
the best means of protein expression were those of Gal-1; this galectin had the highest means
of expression in all culture mediums. Friederike Gieseke and al. confirm our result; thus, they
report that Gal-1 is highly expressed in MSCs. [27]
The results of the RT-PCR are in accordance with those of the flow cytometry. Thus, the RT-
PCR applied to RNA of the MSCs revealed that galectins (Gal-1, Gal-9, Gal-11, and Gal-13) are
expressed by both undifferentiated and differentiated BM-MSCs. So, before the induction of
the differentiation process, the MSCs cultivated in the standard medium expressed Gal-1,
Gal-9, Gal-11, but not Gal-13, while the MSCs cultivated in the mediums enriched by the HPL
expressed only the Gal-1. Nevertheless, after the induction of the MSCs differentiation, first
we observed that Gal-1, Gal-9, Gal-11 were no more expressed in the standard culture’s
medium (alpha MEM+ FGF2) while we detected the expression of Gal-13 in the adipocytes.
Second, when examining the expression of galectins by MSCs cultivated in mediums contain‐
ing the HPL we noticed the presence of Gal-1, Gal-9 with a low expression, Gal-11 in both
adipocytes and VMLs and finally Gal-13 in adipocytes.
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We noted that MSCs expressed the galectins constitutively, but this expression was modulated
differently depending on the type of the galectin the culture’s stage and the composition of
the culture medium.
These findings are in agreement with previous reports. Thus, Friederike Gieseke and al. [27]
claim that m RNAs of Gal-1, Gal-3, -8 and -9 were detected in MSCs by the RT-PCR and when
performing a quantitative real time –PCR the m RNAs of Gal-3, -8 and -9 were detected to a
lesser extent than Gal-1 which is similar to the results we obtained when performing the flow
cytometry.
Najar M and al. [14] confirmed the constitutive expression of galectin-1 m RNA by BM-MSCs.
Regarding Gal-3 Ju-Yeon Kim and al. [28] demonstrated that Gal-3 is secreted by UCB-MSC
under pathological conditions whereas low level of GAL-3 was detected by Western blot
analysis in conditioned medium of naïve UCB-MSC. This report is in contrast with our results
since we confirmed the absence of galectins’ in both membranes and RNAs of UC-MSCs.
The present study provides new insights concerning the expression of the galectins by the
MSCs. According to our observations and the reports mentioned above the galectins are
located both in nuclear and membrane levels. This suggests that the galectins are released by
MSCs. Because of their their multilineage differentiation potential, immunomodulatory and
anti-inflammatory properties, MSCs have become increasingly attractive as a therapeutic
approach. Careful characterization of MSC physiology and the effects of culture mediums
context on their proliferation differentiation and molecules’ secretion will increase the safety
and efficiency of MSCs in clinical settings.
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